Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults

Conclusions: The highest dose level planned for this portion of the trial, 3.0 mg of ixazomib, was reached with 1 DLT and is the recommended dose for induction in the next portion of this study, which will seek to determine a safe ixazomib dose in combination with conventional consolidation therapy. That no neurotoxicity was encountered was reassuring, and the remission rate in this older adult population is favorable.Table.DisclosuresAmrein: Takeda: Research Funding. Attar: Agios: Employment, Equity Ownership. Brunner: Takeda: Research Funding; Novartis: Research Funding; Celgene: Consultancy, Research Funding. Fathi: Celgene: Consultancy, Honoraria, Research Funding; Boston Biomedical: Consultancy, Honoraria; Astellas: Honoraria; Agios: Honoraria, Research Funding; Jazz: Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria.

Source: Blood - November 21, 2018 Category: Hematology Authors: Amrein, P. C., Attar, E. C., Blonquist, T. M., Brunner, A. M., Hobbs, G. S., Hock, H., McAfee, S., Moran, J. A., Bergeron, M., Foster, J., Bertoli, C., McGregor, K., Macrae, M., Burke, M., Behnan, T. T., Som, T. T., Ramos, A. Y., Vartanian, M. K., Lombard Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster III Source Type: research